Recent statements from U.S. President Donald Trump regarding the reduction of prescription drug prices have led to significant shifts in financial markets. The decision, aimed at aligning U.S. drug prices with those in other countries, triggered a sharp response from stock markets in Europe and Asia. Pharmaceutical companies, in particular, saw substantial declines, which may have implications for their future.